Go to main contents

International Cooperation


SHARE 링크연결 공유 인쇄

Official announcement on international collaborative research for Emerging Virus and variants sponsored by Korea National Institute of Health, KCDC

Update 06.04.2023



The Korea National Institute of Health (KNIH), a research organization in the umbrella of Korea Diseases Control and Prevention Agency (KDCA) is devoted for promoting the public health through the research on infectious and non-infectious diseases.

In the facing and responds to COVID-19 global pandemic, it has noticed that infectious disease is the single biggest concerns worldwide in public health. About emerging and re-emerging infectious agents, such as SARS-CoV-2 and high risk pathogens causing hemorrhagic fever, are required various studies to understand its biology and pathogenesis in the host. Ensuring global health securities to high-risk pathogens that could cause severe lethality in human infection, international cooperation is the most important and required for the prevention and control. In the preparedness and control the infectious agent such as VHFs and others what classified in BSL4 biohazard pathogens, we pointed out to enhance foundation and capabilities for emergency response such as next-generated techniques-based diagnosis, therapeutics and vaccine with various novel-platforms.

Therefore, KNIH intend to strengthen the international network on cooperative research for laboratory study with research institutes (or countries) through collaborative research including build-up cooperative research on therapeutics and evaluation platform and look for the other potentials for advanced research on other concerned viral diseases.



1. Title   

Establishment of core-control platform through International Collaborative Research for emerging and re-emerging virus infection


2. Funding

Annual fund for active project described as above will be about USD 75,500 (KRW 100,000,000) per year. The total or yearly budget will be adjusted with the results of evaluation.

3. Research period : 2023 (after the contract) – December 2025

(1st  Year) 2023. After the contract – December 31 2023

(2nd Year) January 1 2024 ~ December 31 2024

(3rd Year) January 1 2025 ~ December 31 2025

4. Objectives (Field of Interesting):

- To build-up a complementary collaborative research platform for preparedness and emergency response to high-risk viral pathogens and novel-variants

  : NBD to research field of diagnosis, therapeutics, and evaluation system and so on.

- Establishment and sharing of non-clinical efficacy evaluation to identify therapeutic agents for infectious diseases and

- Sharing of research resources including clinical specimens, pathogens, and genetic materials

- Expansion and Strengthen of research infrastructures via international collaboration against emerging and re-emerging infectious diseases in specialized research institute in aboard

- Enforcement of capacity through training of staff and/or sharing the practical experience between both agencies



5. Affiliation: Governmental Institute, University, Hospital, etc

-(Consideration) Securing BSL3 research facilities and prioritizing institutions capable of researching BL4 handling pathogens

 6. Reporting system

   - The application should be written in MS word English and submitted before 13 April, 2023 via e-mail


< Address for Airmail >

Division of Emerging Virus & Vector Research

Center for Emerging Virus Research, National Institute of Health

Korea Disease Control and Prevention Agency

TEL : +82-43-719- 8510   FAX : +82-43-719-8519,  email :limhy0919@korea.kr